Identity and analytical detection
Mass-spectrometry research has specifically examined TB-500 as a synthetic Tβ4-related peptide.
Product images are for illustrative reference only. Final label layout and packaging details may vary by batch or production run. Product identity, strength and batch-specific documentation are provided separately and remain product-specific.
NOREXA PEPTIDES / RESEARCH MATERIAL
TB-50010 mg
Lyophilized Peptide — Single vial
TB-500 10 mg supplied exclusively as a laboratory research material. Available batch documentation is published only under its corresponding batch record.
Out of stock
Pricing confirmed separately
- RESEARCH FOCUS
- Tissue Repair & Recovery
QUANTITY
Research areas
FOR LABORATORY RESEARCH USE ONLY.
VERIFY BATCH →Not for human or animal consumption.
Not intended to diagnose, treat, cure or prevent any disease.
RESEARCH & TECHNICAL OVERVIEW
TB-500
10 mg
TB-500 is a common research designation associated with a synthetic peptide related to an active region of thymosin beta-4 (Tβ4). It should not be treated as automatically identical to the full endogenous 43-amino-acid Tβ4 protein.
The current NOREXA record does not publish the TB-500 sequence or salt/form. Accordingly, the page distinguishes direct TB-500 analytical literature from broader Tβ4 biology and avoids assigning full-length Tβ4 properties to an unverified fragment.
RESEARCH SCOPE
For research use only. Not for human or veterinary use. Published findings describe the compound or related research systems; they are not claims about this NOREXA batch.
SCIENTIFIC CONTEXT
Structured.
Source-led.
Longer technical information is grouped for easier reading on desktop and mobile.
01Natural Biological Context+
Full-length thymosin beta-4 is an endogenous actin-binding peptide found in mammalian cells. TB-500 is a synthetic research designation; exact equivalence depends on the documented sequence and form.
02Research Mechanisms+
Actin and cell migration
Full-length Tβ4 literature describes actin sequestration and endothelial-cell migration; this context does not prove identical activity for an unspecified TB-500 fragment.
Preclinical repair models
Animal literature on full-length Tβ4 has examined vascular and wound-response pathways, with the identity limitation noted above.
03Research Applications+
- Analytical identification of TB-500-related material.
- Comparative peptide-fragment and full-length Tβ4 research.
- Actin-binding and cell-migration studies only where the exact sequence supports the model.
04Laboratory Research Preparation+
Lyophilized material may require preparation as a laboratory solution before use in an in-vitro assay. The solvent or buffer and working concentration should follow the applicable protocol and documentation for the exact molecular form.
This page intentionally provides no human dosing calculations, syringe-unit conversions, administration route or treatment schedule. Preparation conditions should be established and recorded by qualified laboratory personnel.
INDEPENDENT VERIFICATION
Batch evidence,
without overclaiming.
Purity alone is not enough. NOREXA distinguishes identity, purity and actual quantity, and publishes results only for the exact batch tested.
CURRENT BATCH / LOT
Independent batch verification: report not currently published
No identity, purity, quantity or batch number is shown as independently verified until exact product-and-lot evidence is available.
OPEN CENTRAL BATCH VERIFICATION →HISTORICAL BATCHES
No historical batch records are currently published for this product.
PRODUCT INFORMATION
Technical
Data.
Verified identity and catalogue information for this NOREXA research material. Unconfirmed fields are omitted.
- Product Name
- TB-500
- Content
- 10 mg
- Form
- Lyophilized Peptide
- Presentation
- Single vial
- Research Classification
- Research Use Only
SELECTED SOURCES
Research
Literature.
Selected literature describes the compound and relevant research pathways; it does not constitute testing or endorsement of this NOREXA batch.
- 01Technical reference↗
Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry
Journal of Chromatography A · 2012
- 02In vitro↗
Thymosin beta-4 stimulates directional migration of human umbilical vein endothelial cells
Journal of Cell Science · 1997
- 03Preclinical↗
Thymosin beta-4 accelerates wound healing
Journal of Investigative Dermatology · 1999
The final two references concern full-length thymosin beta-4 and are included as parent-molecule context only; they do not establish the identity or performance of this NOREXA TB-500 material.
PRODUCT FAQ
TB-500
questions.
01Is TB-500 the same as thymosin beta-4?+
Not automatically. TB-500 is a synthetic research designation associated with a Tβ4-related region; exact equivalence requires a verified sequence.
02Why is the sequence not shown?+
The current verified NOREXA product record does not publish it, so the page does not guess.
03Why are Tβ4 papers cited?+
They provide clearly labelled parent-molecule context. They do not test this product or prove that an unspecified fragment behaves like full-length Tβ4.
04Why is storage omitted?+
Without a verified sequence and form, a solution-stability claim from another reagent would be scientifically unreliable.
SECTION 01 — STANDARDS
Scientific transparency,
documented for research.
01 / 03Scientific Integrity
Independent analytical results are presented as reported by the testing laboratory, without altering the laboratory’s findings.
02 / 03Batch Traceability
Each batch is assigned a record linking the product to its available technical and independent testing documentation.
03 / 03Quality Documentation
Available batch documentation is organized under the corresponding batch number for clear reference.